Top

Clinical and Translational Oncology

Published in:

01-03-2011 | Correspondence

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Authors: Carmen Balañá, Olatz Etxaniz, Cristina Bugés, Alex Martínez

Published in: Clinical and Translational Oncology | Issue 3/2011

Title: Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
Authors: Carmen Balañá
Olatz Etxaniz
Cristina Bugés
Alex Martínez
Publication date: 01-03-2011
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 3/2011
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-011-0642-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 3/2011

Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

Patients, pathways, progress

New technologies in cancer. Protein microarrays for biomarker discovery

Treatment recommendations for metastatic colorectal cancer

Mechanism of hot flashes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer